Tito Fojo - Publications

Affiliations: 
1998- NIH (NCI) 

187 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Sigel K, Zhou M, Park YA, Mutetwa T, Nadkarni G, Yeh C, Polak P, Sigel C, Conroy T, Juzyna B, Ychou M, Fojo T, Wisnivesky JP, Bates SE. Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in veterans. Seminars in Oncology. PMID 33714591 DOI: 10.1053/j.seminoncol.2021.02.001  0.56
2021 Blagoev KB, Iordanov R, Zhou M, Fojo T, Bates SE. Drug resistant cells with very large proliferative potential grow exponentially in metastatic prostate cancer. Oncotarget. 12: 15-21. PMID 33456710 DOI: 10.18632/oncotarget.27855  0.56
2020 Fojo T, Huff L, Litman T, Im K, Edgerly M, Del Rivero J, Pittaluga S, Merino M, Bates SE, Dean M. Metastatic and recurrent adrenocortical cancer is not defined by its genomic landscape. Bmc Medical Genomics. 13: 165. PMID 33148256 DOI: 10.1186/s12920-020-00809-7  0.56
2019 Leuva H, Sigel K, Zhou M, Wilkerson J, Aggen DH, Park YA, Anderson CB, Hsu TM, Langhoff E, McWilliams G, Drake CG, Simon R, Bates SE, Fojo T. A novel approach to assess real-world efficacy of cancer therapy in metastatic prostate cancer. Analysis of national data on Veterans treated with abiraterone and enzalutamide. Seminars in Oncology. PMID 31757478 DOI: 10.1053/J.Seminoncol.2019.11.004  0.56
2019 Burotto M, Wilkerson J, Stein WD, Bates SE, Fojo T. Adjuvant and neoadjuvant cancer therapies: A historical review and a rational approach to understand outcomes. Seminars in Oncology. PMID 30738604 DOI: 10.1053/J.Seminoncol.2019.01.002  0.56
2018 Bauml JM, Vinnakota R, Anna Park YH, Bates SE, Fojo T, Aggarwal C, Di Stefano J, Knepley C, Limaye S, Mamtani R, Wisnivesky J, Damjanov N, Langer CJ, Cohen RB, Sigel K. Cisplatin versus cetuximab with definitive concurrent radiotherapy for head and neck squamous cell carcinoma: An analysis of veterans health affairs data. Cancer. PMID 30341983 DOI: 10.1002/Cncr.31816  0.56
2018 Bauml JM, Vinnakota R, Anna Park YH, Bates SE, Fojo T, Aggarwal C, Limaye S, Damjanov N, Di Stefano J, Ciunci C, Genden EM, Wisnivesky JP, Ferrandino R, Mamtani R, Langer CJ, et al. Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck. Journal of the National Cancer Institute. PMID 30239887 DOI: 10.1093/Jnci/Djy133  0.56
2018 Balasubramaniam S, Redon CE, Peer CJ, Bryla C, Lee MJ, Trepel JB, Tomita Y, Rajan A, Giaccone G, Bonner WM, Figg WD, Fojo T, Piekarz RL, Bates SE. Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung. Anti-Cancer Drugs. PMID 29420340 DOI: 10.1097/Cad.0000000000000596  0.56
2016 Wilkerson J, Abdallah K, Hugh-Jones C, Curt G, Rothenberg M, Simantov R, Murphy M, Morrell J, Beetsch J, Sargent DJ, Scher HI, Lebowitz P, Simon R, Stein WD, Bates SE, ... Fojo T, et al. Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis. The Lancet. Oncology. PMID 27979599 DOI: 10.1016/S1470-2045(16)30633-7  0.56
2016 Payabyab EC, Balasubramaniam S, Edgerly M, Velarde M, Merino MJ, Venkatesan AM, Leuva H, Litman T, Bates SE, Fojo T. Adrenocortical Cancer: A Molecularly Complex Disease Where Surgery Matters. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 22: 4989-5000. PMID 27742785 DOI: 10.1158/1078-0432.CCR-16-1570  0.56
2016 O'Sullivan CC, Lindenberg M, Bryla C, Patronas N, Peer CJ, Amiri-Kordestani L, Davarpanah N, Gonzalez EM, Burotto M, Choyke P, Steinberg SM, Liewehr DJ, Figg WD, Fojo T, Balasubramaniam S, et al. ANG1005 for breast cancer brain metastases: correlation between (18)F-FLT-PET after first cycle and MRI in response assessment. Breast Cancer Research and Treatment. PMID 27620882 DOI: 10.1007/S10549-016-3972-Z  0.56
2016 Gharwan H, Lai C, Grant C, Dunleavy K, Steinberg SM, Shovlin M, Fojo T, Wilson WH. Female fertility following dose-adjusted EPOCH-R chemotherapy in primary mediastinal B-cell lymphomas. Leukemia & Lymphoma. 1-9. PMID 27183887 DOI: 10.3109/10428194.2015.1118476  0.56
2016 Fojo T. Precision oncology: a strategy we were not ready to deploy. Seminars in Oncology. 43: 9-12. PMID 26970119 DOI: 10.1053/j.seminoncol.2016.01.005  0.56
2016 Fojo T. Moving a pioneer journal into the future. Seminars in Oncology. 43: 1. PMID 26970116 DOI: 10.1053/j.seminoncol.2016.01.004  0.56
2016 Bates SE, Fojo T. Clinical trials: New drug for pancreatic cancer highlights the dual effect of regulatory approvals. Nature Reviews. Clinical Oncology. PMID 26902963 DOI: 10.1038/nrclinonc.2016.22  0.56
2016 Massey PR, Wang R, Prasad V, Bates SE, Fojo T. Assessing the Eventual Publication of Clinical Trial Abstracts Submitted to a Large Annual Oncology Meeting. The Oncologist. PMID 26888691 DOI: 10.1634/Theoncologist.2015-0516  0.56
2016 Prasad V, Fojo T, Brada M. Precision oncology: origins, optimism, and potential. The Lancet. Oncology. 17: e81-6. PMID 26868357 DOI: 10.1016/S1470-2045(15)00620-8  0.56
2016 Fojo T, Lo AW. Price, value, and the cost of cancer drugs. The Lancet. Oncology. 17: 3-5. PMID 26758749 DOI: 10.1016/S1470-2045(15)00564-1  0.56
2015 Basseville A, Bates S, Fojo T. Pancreatic cancer: Targeting KRAS and the vitamin D receptor via microtubules. Nature Reviews. Clinical Oncology. 12: 442-4. PMID 26169922 DOI: 10.1038/Nrclinonc.2015.125  0.56
2015 Burotto M, Edgerly M, Poruchynsky M, Velarde M, Wilkerson J, Kotz H, Bates S, Balasubramaniam S, Fojo T. Phase II Clinical Trial of Ixabepilone in Metastatic Cervical Carcinoma. The Oncologist. 20: 725-6. PMID 26040622 DOI: 10.1634/Theoncologist.2015-0104  0.56
2015 Massey PR, Prasad V, Figg WD, Fojo T. Multiplying therapies and reducing toxicity in metastatic melanoma. Cancer Biology & Therapy. 16: 1014-8. PMID 26016850 DOI: 10.1080/15384047.2015.1046650  0.56
2015 Martucci VL, Emaminia A, Del Rivero J, Lechan RM, Magoon BT, Galia A, Fojo T, Leung S, Lorusso R, Jimenez C, Shulkin BL, Audibert JL, Adams KT, Rosing DR, Vaidya A, et al. Succinate dehydrogenase gene mutations in cardiac paragangliomas. The American Journal of Cardiology. 115: 1753-9. PMID 25896150 DOI: 10.1016/J.Amjcard.2015.03.020  0.56
2015 Bates SE, Eisch R, Ling A, Rosing D, Turner M, Pittaluga S, Prince HM, Kirschbaum MH, Allen SL, Zain J, Geskin LJ, Joske D, Popplewell L, Cowen EW, Jaffe ES, ... ... Fojo T, et al. Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data. British Journal of Haematology. 170: 96-109. PMID 25891346 DOI: 10.1111/Bjh.13400  0.56
2015 Burotto M, Prasad V, Fojo T. Non-inferiority trials: why oncologists must remain wary. The Lancet. Oncology. 16: 364-6. PMID 25846084 DOI: 10.1016/S1470-2045(15)70129-4  0.56
2015 Burotto M, Manasanch EE, Wilkerson J, Fojo T. Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials. The Oncologist. 20: 400-10. PMID 25795635 DOI: 10.1634/Theoncologist.2014-0154  0.56
2015 Burotto M, Tageja N, Rosenberg A, Mahalingam S, Quezado M, Velarde M, Edgerly M, Fojo T. Brain metastasis in patients with adrenocortical carcinoma: a clinical series. The Journal of Clinical Endocrinology and Metabolism. 100: 331-6. PMID 25412413 DOI: 10.1210/Jc.2014-2650  0.56
2014 Fojo T, Giannakakou P. Decade in review-funding in cancer research: National Cancer Institute awards-a work in progress. Nature Reviews. Clinical Oncology. 11: 634-6. PMID 25311348 DOI: 10.1038/Nrclinonc.2014.173  0.56
2014 Blagoev KB, Wilkerson J, Stein WD, Yang J, Bates SE, Fojo T. Therapies with diverse mechanisms of action kill cells by a similar exponential process in advanced cancers. Cancer Research. 74: 4653-62. PMID 25183789 DOI: 10.1158/0008-5472.Can-14-0420  0.56
2014 Fojo T, Mailankody S, Lo A. Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture. Jama Otolaryngology-- Head & Neck Surgery. 140: 1225-36. PMID 25068501 DOI: 10.1001/jamaoto.2014.1570  0.56
2014 Schovanek J, Martucci V, Wesley R, Fojo T, Del Rivero J, Huynh T, Adams K, Kebebew E, Frysak Z, Stratakis CA, Pacak K. The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study. Bmc Cancer. 14: 523. PMID 25048685 DOI: 10.1186/1471-2407-14-523  0.56
2014 Taïeb D, Kaliski A, Boedeker CC, Martucci V, Fojo T, Adler JR, Pacak K. Current approaches and recent developments in the management of head and neck paragangliomas Endocrine Reviews. 35: 795-819. PMID 25033281 DOI: 10.1210/er.2014-1026  0.56
2014 Burotto M, Wilkerson J, Stein W, Motzer R, Bates S, Fojo T. Continuing a cancer treatment despite tumor growth may be valuable: sunitinib in renal cell carcinoma as example. Plos One. 9: e96316. PMID 24796484 DOI: 10.1371/Journal.Pone.0096316  0.56
2014 Prasad V, Massey PR, Fojo T. Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 1620-9. PMID 24711558 DOI: 10.1200/Jco.2013.53.0204  0.56
2014 O'Sullivan C, Edgerly M, Velarde M, Wilkerson J, Venkatesan AM, Pittaluga S, Yang SX, Nguyen D, Balasubramaniam S, Fojo T. The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer. The Journal of Clinical Endocrinology and Metabolism. 99: 1291-7. PMID 24423320 DOI: 10.1210/Jc.2013-2298  0.56
2014 Aggarwal A, Ginsburg O, Fojo T. Cancer economics, policy and politics: What informs the debate? Perspectives from the EU, Canada and US Journal of Cancer Policy. 2: 1-11. DOI: 10.1016/J.Jcpo.2014.02.002  0.56
2013 Patel D, Boufraqech M, Jain M, Zhang L, He M, Gesuwan K, Gulati N, Nilubol N, Fojo T, Kebebew E. MiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors. Surgery. 154: 1224-8; discussion 1. PMID 24238045 DOI: 10.1016/J.Surg.2013.06.022  0.56
2013 Acquavella N, Fojo T. Renal cell carcinoma: trying but failing to improve the only curative therapy. Journal of Immunotherapy (Hagerstown, Md. : 1997). 36: 459-61. PMID 24145356 DOI: 10.1097/Cji.0000000000000002  0.56
2013 Ho J, Turkbey B, Edgerly M, Alimchandani M, Quezado M, Camphausen K, Fojo T, Kaushal A. Role of radiotherapy in adrenocortical carcinoma. Cancer Journal (Sudbury, Mass.). 19: 288-94. PMID 23867507 DOI: 10.1097/Ppo.0B013E31829E3221  0.56
2013 Amiri-Kordestani L, Luchenko V, Peer CJ, Ghafourian K, Reynolds J, Draper D, Frye R, Woo S, Venzon D, Wright J, Skarulis M, Figg WD, Fojo T, Bates SE, Piekarz RL. Phase I trial of a new schedule of romidepsin in patients with advanced cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 4499-507. PMID 23757352 DOI: 10.1158/1078-0432.Ccr-13-0095  0.56
2013 Pacak K, Jochmanova I, Prodanov T, Yang C, Merino MJ, Fojo T, Prchal JT, Tischler AS, Lechan RM, Zhuang Z. New syndrome of paraganglioma and somatostatinoma associated with polycythemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 1690-8. PMID 23509317 DOI: 10.1200/Jco.2012.47.1912  0.56
2013 Komlodi-Pasztor E, Sackett DL, Fojo T. Tales of how great drugs were brought down by a flawed rationale--response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 1304. PMID 23393076 DOI: 10.1158/1078-0432.CCR-12-2058  0.56
2013 Fojo T, Bates S. Mechanisms of resistance to PARP inhibitors--three and counting. Cancer Discovery. 3: 20-3. PMID 23319766 DOI: 10.1158/2159-8290.Cd-12-0514  0.56
2013 Stein WD, Wilkerson J, Manasanch E, Zhuang SH, Bates SE, Fojo T. Abstract 5152: Estimating the fraction of a tumor that is killed by a drug. Cancer Research. 73: 5152-5152. DOI: 10.1158/1538-7445.Am2013-5152  0.56
2012 Zhuang Z, Yang C, Lorenzo F, Merino M, Fojo T, Kebebew E, Popovic V, Stratakis CA, Prchal JT, Pacak K. Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. The New England Journal of Medicine. 367: 922-30. PMID 22931260 DOI: 10.1056/Nejmoa1205119  0.56
2012 Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B, Sorbye H, Torpy DJ, Stepan V, Schteingart DE, Arlt W, ... ... Fojo T, et al. Combination chemotherapy in advanced adrenocortical carcinoma. The New England Journal of Medicine. 366: 2189-97. PMID 22551107 DOI: 10.1056/Nejmoa1200966  0.56
2012 Amiri-Kordestani L, Fojo T. Why do phase III clinical trials in oncology fail so often? Journal of the National Cancer Institute. 104: 568-9. PMID 22491346 DOI: 10.1093/Jnci/Djs180  0.56
2012 Kelly RJ, Robey RW, Chen CC, Draper D, Luchenko V, Barnett D, Oldham RK, Caluag Z, Frye AR, Steinberg SM, Fojo T, Bates SE. A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumors. The Oncologist. 17: 512. PMID 22416063 DOI: 10.1634/Theoncologist.2012-0080  0.56
2012 Murphy RF, Komlodi-Pasztor E, Robey R, Balis FM, Farrell NP, Fojo T. Retained platinum uptake and indifference to p53 status make novel transplatinum agents active in platinum-resistant cells compared to cisplatin and oxaliplatin. Cell Cycle (Georgetown, Tex.). 11: 963-73. PMID 22333583 DOI: 10.4161/Cc.11.5.19447  0.56
2012 Blagoev KB, Wilkerson J, Fojo T. Hazard ratios in cancer clinical trials--a primer. Nature Reviews. Clinical Oncology. 9: 178-83. PMID 22290283 DOI: 10.1038/Nrclinonc.2011.217  0.56
2012 Fojo T, Bates S, Chabner BA. Editor's Note ...Clinical Trial Reports: A New Section. The Oncologist. 17: 11-2. PMID 22286772 DOI: 10.1634/Theoncologist.2012-0040  0.56
2012 Datrice NM, Langan RC, Ripley RT, Kemp CD, Steinberg SM, Wood BJ, Libutti SK, Fojo T, Schrump DS, Avital I. Operative management for recurrent and metastatic adrenocortical carcinoma. Journal of Surgical Oncology. 105: 709-13. PMID 22189845 DOI: 10.1002/Jso.23015  0.56
2012 Fonte JS, Robles JF, Chen CC, Reynolds J, Whatley M, Ling A, Mercado-Asis LB, Adams KT, Martucci V, Fojo T, Pacak K. False-negative ¹²³I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease. Endocrine-Related Cancer. 19: 83-93. PMID 22167067 DOI: 10.1530/Erc-11-0243  0.56
2012 Stein WD, Wilkerson J, Adesunloye B, Madan R, Bates SE, Wells S, Dahut W, Ning Y, Zhuang SH, Motzer RJ, Fojo T. Abstract 765: Growth rates of tumors with numerous histologies remain constant while patients are on therapy Cancer Research. 72: 765-765. DOI: 10.1158/1538-7445.Am2012-765  0.56
2012 Fojo T, Amiri-Kordestani L, Bates SE. Response Journal of the National Cancer Institute. 104: 718. DOI: 10.1093/jnci/djs166  0.56
2011 Fojo T, Amiri-Kordestani L, Bates SE. Potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer. Journal of the National Cancer Institute. 103: 1738-40. PMID 22045362 DOI: 10.1093/Jnci/Djr386  0.56
2011 King KS, Prodanov T, Kantorovich V, Fojo T, Hewitt JK, Zacharin M, Wesley R, Lodish M, Raygada M, Gimenez-Roqueplo AP, McCormack S, Eisenhofer G, Milosevic D, Kebebew E, Stratakis CA, et al. Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4137-42. PMID 21969497 DOI: 10.1200/Jco.2011.34.6353  0.56
2011 Kemp CD, Ripley RT, Mathur A, Steinberg SM, Nguyen DM, Fojo T, Schrump DS. Pulmonary resection for metastatic adrenocortical carcinoma: the National Cancer Institute experience. The Annals of Thoracic Surgery. 92: 1195-200. PMID 21958764 DOI: 10.1016/J.Athoracsur.2011.05.013  0.56
2011 Sullivan R, Peppercorn J, Sikora K, Zalcberg J, Meropol NJ, Amir E, Khayat D, Boyle P, Autier P, Tannock IF, Fojo T, Siderov J, Williamson S, Camporesi S, McVie JG, et al. Delivering affordable cancer care in high-income countries. The Lancet. Oncology. 12: 933-80. PMID 21958503 DOI: 10.1016/S1470-2045(11)70141-3  0.56
2011 Sackett DL, Fojo T. Taccalonolides: a microtubule stabilizer poses a new puzzle with old pieces. Cell Cycle (Georgetown, Tex.). 10: 3233-4. PMID 21946521 DOI: 10.4161/Cc.10.19.17126  0.56
2011 Patterson EE, Holloway AK, Weng J, Fojo T, Kebebew E. MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer. 117: 1630-9. PMID 21472710 DOI: 10.1002/Cncr.25724  0.56
2011 Ripley RT, Kemp CD, Davis JL, Langan RC, Royal RE, Libutti SK, Steinberg SM, Wood BJ, Kammula US, Fojo T, Avital I. Liver resection and ablation for metastatic adrenocortical carcinoma. Annals of Surgical Oncology. 18: 1972-9. PMID 21301973 DOI: 10.1245/S10434-011-1564-Z  0.56
2011 Komlodi-Pasztor E, Sackett D, Wilkerson J, Fojo T. Mitosis is not a key target of microtubule agents in patient tumors. Nature Reviews. Clinical Oncology. 8: 244-50. PMID 21283127 DOI: 10.1038/Nrclinonc.2010.228  0.56
2011 Stein WD, Gulley JL, Schlom J, Madan RA, Dahut W, Figg WD, Ning YM, Arlen PM, Price D, Bates SE, Fojo T. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 907-17. PMID 21106727 DOI: 10.1200/Jco.2012.30.5_Suppl.133  0.56
2011 Kelly RJ, Draper D, Chen CC, Robey RW, Figg WD, Piekarz RL, Chen X, Gardner ER, Balis FM, Venkatesan AM, Steinberg SM, Fojo T, Bates SE. A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 569-80. PMID 21081657 DOI: 10.1158/1078-0432.Ccr-10-1725  0.56
2011 Komlodi-Pasztor E, Sackett D, Wilkerson J, Fojo T. (Not) too early to say, "no targeting of mitosis!" Nature Reviews Clinical Oncology. 8: 444. DOI: 10.1038/Nrclinonc.2010.228-C2  0.56
2010 Balasubramaniam S, Fojo T. Practical considerations in the evaluation and management of adrenocortical cancer. Seminars in Oncology. 37: 619-26. PMID 21167380 DOI: 10.1053/J.Seminoncol.2010.10.011  0.56
2010 Fojo T, Wilkerson J. Bevacizumab and breast cancer: the E2100 outlier. The Lancet. Oncology. 11: 1117-9. PMID 21126685 DOI: 10.1016/S1470-2045(10)70259-X  0.56
2010 Madan RA, Gulley JL, Fojo T, Dahut WL. Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. The Oncologist. 15: 969-75. PMID 20798195 DOI: 10.1634/Theoncologist.2010-0129  0.56
2010 Huff LM, Sackett DL, Poruchynsky MS, Fojo T. Microtubule-disrupting chemotherapeutics result in enhanced proteasome-mediated degradation and disappearance of tubulin in neural cells. Cancer Research. 70: 5870-9. PMID 20587529 DOI: 10.1158/0008-5472.Can-09-4281  0.56
2010 Huang H, Menefee M, Edgerly M, Zhuang S, Kotz H, Poruchynsky M, Huff LM, Bates S, Fojo T. A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 1634-41. PMID 20179242 DOI: 10.1158/1078-0432.Ccr-09-0379  0.56
2010 Bates SE, Zhan Z, Steadman K, Obrzut T, Luchenko V, Frye R, Robey RW, Turner M, Gardner ER, Figg WD, Steinberg SM, Ling A, Fojo T, To KW, Piekarz RL. Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. British Journal of Haematology. 148: 256-67. PMID 19874311 DOI: 10.1111/J.1365-2141.2009.07954.X  0.56
2010 Veytsman I, Fojo T. Reply to A. Berruti et al Journal of Clinical Oncology. 28: e403. DOI: 10.1200/Jco.2010.28.0321  0.56
2010 Kelly RJ, Robey R, Draper D, Chen C, Venkatesan AM, Figg WD, Gardner E, Piekarz R, Balis F, Fojo T, Bates SE. Abstract 3527: A pharmacodynamic study of docetaxel in combination with the p-glycoprotein antagonist, tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer Cancer Research. 70: 3527-3527. DOI: 10.1158/1538-7445.Am10-3527  0.56
2009 Wilkerson J, Fojo T. Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival. Cancer Journal (Sudbury, Mass.). 15: 379-85. PMID 19826357 DOI: 10.1097/Ppo.0B013E3181Bef8Cd  0.56
2009 Vidaurre T, Wilkerson J, Simon R, Bates SE, Fojo T. Stable disease is not preferentially observed with targeted therapies and as currently defined has limited value in drug development. Cancer Journal (Sudbury, Mass.). 15: 366-73. PMID 19826355 DOI: 10.1097/Ppo.0B013E3181B9D37B  0.56
2009 Fojo T. From the guest editor: monitoring of therapeutic response to cancer treatment. Cancer Journal (Sudbury, Mass.). 15: 352-3. PMID 19826352 DOI: 10.1097/Ppo.0B013E3181Be244D  0.56
2009 Veytsman I, Nieman L, Fojo T. Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4619-29. PMID 19667279 DOI: 10.1200/Jco.2008.17.2775  0.56
2009 He J, Makey D, Fojo T, Adams KT, Havekes B, Eisenhofer G, Sullivan P, Lai EW, Pacak K. Successful chemotherapy of hepatic metastases in a case of succinate dehydrogenase subunit B-related paraganglioma. Endocrine. 36: 189-93. PMID 19618298 DOI: 10.1007/S12020-009-9219-6  0.56
2009 Komlodi-Pasztor E, Trostel S, Sackett D, Poruchynsky M, Fojo T. Impaired p53 binding to importin: a novel mechanism of cytoplasmic sequestration identified in oxaliplatin-resistant cells. Oncogene. 28: 3111-20. PMID 19581934 DOI: 10.1038/Onc.2009.166  0.56
2009 Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. Journal of the National Cancer Institute. 101: 1044-8. PMID 19564563 DOI: 10.1093/Jnci/Djp177  0.56
2009 Abraham J, Edgerly M, Wilson R, Chen C, Rutt A, Bakke S, Robey R, Dwyer A, Goldspiel B, Balis F, Van Tellingen O, Bates SE, Fojo T. A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 3574-82. PMID 19417029 DOI: 10.1158/1078-0432.Ccr-08-0938  0.56
2009 Widemann BC, Goodspeed W, Goodwin A, Fojo T, Balis FM, Fox E. Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 550-6. PMID 19075272 DOI: 10.1200/Jco.2008.17.6644  0.56
2008 Hu J, Xia X, Cheng A, Wang G, Luo X, Reed MF, Fojo T, Oetting A, Gong J, Yen PM. A peptide inhibitor derived from p55PIK phosphatidylinositol 3-kinase regulatory subunit: a novel cancer therapy. Molecular Cancer Therapeutics. 7: 3719-28. PMID 19074847 DOI: 10.1158/1535-7163.Mct-08-0499  0.56
2008 Huang H, Fojo T. Adjuvant mitotane for adrenocortical cancer--a recurring controversy. The Journal of Clinical Endocrinology and Metabolism. 93: 3730-2. PMID 18842984 DOI: 10.1210/Jc.2008-0579  0.56
2008 Stein WD, Figg WD, Dahut W, Stein AD, Hoshen MB, Price D, Bates SE, Fojo T. Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data. The Oncologist. 13: 1046-54. PMID 18838440 DOI: 10.1634/Theoncologist.2008-0075  0.56
2008 Stein WD, Yang J, Bates SE, Fojo T. Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage. The Oncologist. 13: 1055-62. PMID 18827177 DOI: 10.1634/Theoncologist.2008-0016  0.56
2008 Huang H, Abraham J, Hung E, Averbuch S, Merino M, Steinberg SM, Pacak K, Fojo T. Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer. 113: 2020-8. PMID 18780317 DOI: 10.1002/Cncr.23812  0.56
2008 Kong HH, Sibaud V, Chanco Turner ML, Fojo T, Hornyak TJ, Chevreau C. Sorafenib-induced eruptive melanocytic lesions. Archives of Dermatology. 144: 820-2. PMID 18559790 DOI: 10.1001/archderm.144.6.820  0.56
2008 Poruchynsky MS, Sackett DL, Robey RW, Ward Y, Annunziata C, Fojo T. Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition. Cell Cycle (Georgetown, Tex.). 7: 940-9. PMID 18414063 DOI: 10.4161/Cc.7.7.5625  0.56
2008 Fojo T. Commentary: Novel therapies for cancer: why dirty might be better. The Oncologist. 13: 277-83. PMID 18378537 DOI: 10.1634/Theoncologist.2007-0090  0.56
2008 Edgerly M, Fojo T. Is there room for improvement in adverse event reporting in the era of targeted therapies? Journal of the National Cancer Institute. 100: 240-2. PMID 18270340 DOI: 10.1093/Jnci/Djm324  0.56
2008 Robey RW, Shukla S, Finley EM, Oldham RK, Barnett D, Ambudkar SV, Fojo T, Bates SE. Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)). Biochemical Pharmacology. 75: 1302-12. PMID 18234154 DOI: 10.1016/J.Bcp.2007.12.001  0.56
2007 Zhuang SH, Hung YE, Hung L, Robey RW, Sackett DL, Linehan WM, Bates SE, Fojo T, Poruchynsky MS. Evidence for microtubule target engagement in tumors of patients receiving ixabepilone. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 7480-6. PMID 18094432 DOI: 10.1158/1078-0432.Ccr-06-2883  0.56
2007 Rixe O, Fojo T. Is cell death a critical end point for anticancer therapies or is cytostasis sufficient? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 7280-7. PMID 18094408 DOI: 10.1158/1078-0432.Ccr-07-2141  0.56
2007 Fojo T, Coley HM. The role of efflux pumps in drug-resistant metastatic breast cancer: new insights and treatment strategies. Clinical Breast Cancer. 7: 749-56. PMID 18021475 DOI: 10.3816/CBC.2007.n.035  0.56
2007 Fojo T, Menefee M. Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 18: v3-8. PMID 17656560 DOI: 10.1093/annonc/mdm172  0.56
2007 Stein WD, Litman T, Fojo T, Bates SE. A database study that identifies genes whose expression correlates, negatively or positively, with 5-year survival of cancer patients. Biochimica Et Biophysica Acta. 1770: 857-71. PMID 17398010 DOI: 10.1016/J.Bbagen.2006.12.013  0.56
2007 Fojo T. Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 10: 59-67. PMID 17350322 DOI: 10.1016/J.Drup.2007.02.002  0.56
2007 Goldsmith ME, Aguila A, Steadman K, Martinez A, Steinberg SM, Alley MC, Waud WR, Bates SE, Fojo T. The histone deacetylase inhibitor FK228 given prior to adenovirus infection can boost infection in melanoma xenograft model systems. Molecular Cancer Therapeutics. 6: 496-505. PMID 17308048 DOI: 10.1158/1535-7163.Mct-06-0431  0.56
2006 Fojo T. Can mutations in gamma-actin modulate the toxicity of microtubule targeting agents? Journal of the National Cancer Institute. 98: 1345-7. PMID 17018774 DOI: 10.1093/Jnci/Djj408  0.56
2006 Trostel SY, Sackett DL, Fojo T. Oligomerization of p53 precedes its association with dynein and nuclear accumulation. Cell Cycle (Georgetown, Tex.). 5: 2253-9. PMID 16969106 DOI: 10.4161/Cc.5.19.3291  0.56
2006 Huff LM, Lee JS, Robey RW, Fojo T. Characterization of gene rearrangements leading to activation of MDR-1. The Journal of Biological Chemistry. 281: 36501-9. PMID 16956878 DOI: 10.1074/Jbc.M602998200  0.56
2006 Niederhuber JE, Fojo T. Treatment of metastatic disease in patients with neuroendocrine tumors. Surgical Oncology Clinics of North America. 15: 511-33, viii. PMID 16882495 DOI: 10.1016/j.soc.2006.05.004  0.56
2006 Bates SE, Rosing DR, Fojo T, Piekarz RL. Challenges of evaluating the cardiac effects of anticancer agents. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 3871-4. PMID 16818679 DOI: 10.1158/1078-0432.Ccr-06-1017  0.56
2006 Piekarz RL, Frye AR, Wright JJ, Steinberg SM, Liewehr DJ, Rosing DR, Sachdev V, Fojo T, Bates SE. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 3762-73. PMID 16778104 DOI: 10.1158/1078-0432.Ccr-05-2095  0.56
2006 Robey RW, Zhan Z, Piekarz RL, Kayastha GL, Fojo T, Bates SE. Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 1547-55. PMID 16533780 DOI: 10.1158/1078-0432.Ccr-05-1423  0.56
2006 Piekarz RL, Frye R, Turner M, Wright J, Allen S, Kirschbaum MH, Zain J, Prince M, Hutchins L, Showe LC, Figg WD, Fojo T, Bates SE. Phase II Trial of Romidepsin, FK228, in Cutaneous and Peripheral T-Cell Lymphoma: Clinical Activity and Molecular Markers. Blood. 108: 2469-2469. DOI: 10.1182/Blood.V108.11.2469.2469  0.56
2006 Piekarz RL, Frye R, Turner M, Wright J, Allen S, Kirschbaum MH, Zain J, Prince M, Hutchins L, Showe LC, Figg WD, Fojo T, Bates SE. Phase II trial of romidepsin (FK228 or depsipeptide) in peripheral T-cell lymphoma: Clinical activity and molecular markers Haematologica Reports. 2: 29-31.  0.56
2005 Huff LM, Wang Z, Iglesias A, Fojo T, Lee JS. Aberrant transcription from an unrelated promoter can result in MDR-1 expression following drug selection in vitro and in relapsed lymphoma samples. Cancer Research. 65: 11694-703. PMID 16357181 DOI: 10.1158/0008-5472.Can-04-1349  0.56
2005 Bates SE, Fojo T. Epidermal growth factor receptor inhibitors: a moving target? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 7203-5. PMID 16243788 DOI: 10.1158/1078-0432.Ccr-05-1845  0.56
2005 Chen KG, Wang YC, Schaner ME, Francisco B, Durán GE, Juric D, Huff LM, Padilla-Nash H, Ried T, Fojo T, Sikic BI. Genetic and epigenetic modeling of the origins of multidrug-resistant cells in a human sarcoma cell line. Cancer Research. 65: 9388-97. PMID 16230402 DOI: 10.1158/0008-5472.Can-04-4133  0.56
2005 Ma ES, Bates WD, Edmunds A, Kelland LR, Fojo T, Farrell N. Enhancement of aqueous solubility and stability employing a trans acetate axis in trans planar amine platinum compounds while maintaining the biological profile. Journal of Medicinal Chemistry. 48: 5651-4. PMID 16134932 DOI: 10.1021/Jm050539D  0.56
2005 Blagosklonny MV, Trostel S, Kayastha G, Demidenko ZN, Vassilev LT, Romanova LY, Bates S, Fojo T. Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors. Cancer Research. 65: 7386-92. PMID 16103091 DOI: 10.1158/0008-5472.Can-04-3433  0.56
2005 Rao VK, Knutsen T, Ried T, Wangsa D, Flynn BM, Langham G, Egorin MJ, Cole D, Balis F, Steinberg SM, Bates S, Fojo T. The extent of chromosomal aberrations induced by chemotherapy in non-human primates depends on the schedule of administration. Mutation Research. 583: 105-19. PMID 15927870 DOI: 10.1016/J.Mrgentox.2005.01.013  0.56
2005 Low JA, Wedam SB, Lee JJ, Berman AW, Brufsky A, Yang SX, Poruchynsky MS, Steinberg SM, Mannan N, Fojo T, Swain SM. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 2726-34. PMID 15837987 DOI: 10.1200/Jco.2005.10.024  0.56
2005 Demidenko ZN, Fojo T, Blagosklonny MV. Complementation of two mutant p53: implications for loss of heterozygosity in cancer. Febs Letters. 579: 2231-5. PMID 15811347 DOI: 10.1016/J.Febslet.2005.03.012  0.56
2005 Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nature Reviews. Cancer. 5: 275-84. PMID 15803154 DOI: 10.1038/Nrc1590  0.56
2005 Zhuang SH, Agrawal M, Edgerly M, Bakke S, Kotz H, Thambi P, Rutt A, Balis FM, Bates S, Fojo T. A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days. Cancer. 103: 1932-8. PMID 15800893 DOI: 10.1002/cncr.20977  0.56
2005 Neeman Z, Sarin S, Coleman J, Fojo T, Wood BJ. Radiofrequency ablation for tumor-related massive hematuria. Journal of Vascular and Interventional Radiology : Jvir. 16: 417-21. PMID 15758142 DOI: 10.1097/01.Rvi.0000147076.02176.13  0.56
2005 Fojo T, Farrell N, Ortuzar W, Tanimura H, Weinstein J, Myers TG. Identification of non-cross-resistant platinum compounds with novel cytotoxicity profiles using the NCI anticancer drug screen and clustered image map visualizations. Critical Reviews in Oncology/Hematology. 53: 25-34. PMID 15607933 DOI: 10.1016/J.Critrevonc.2004.09.008  0.56
2005 Stein WD, Litman T, Fojo T, Bates SE. Differential expression of cell adhesion genes: implications for drug resistance. International Journal of Cancer. Journal International Du Cancer. 113: 861-5. PMID 15514970 DOI: 10.1002/Ijc.20671  0.56
2004 Muggia FM, Fojo T. Platinums: extending their therapeutic spectrum. Journal of Chemotherapy (Florence, Italy). 16: 77-82. PMID 15688617 DOI: 10.1179/joc.2004.16.4.77  0.56
2004 Poruchynsky MS, Kim JH, Nogales E, Annable T, Loganzo F, Greenberger LM, Sackett DL, Fojo T. Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability. Biochemistry. 43: 13944-54. PMID 15518543 DOI: 10.1021/Bi049300+  0.56
2004 Loganzo F, Hari M, Annable T, Tan X, Morilla DB, Musto S, Zask A, Kaplan J, Minnick AA, May MK, Ayral-Kaloustian S, Poruchynsky MS, Fojo T, Greenberger LM. Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin. Molecular Cancer Therapeutics. 3: 1319-27. PMID 15486199  0.56
2004 Bates SE, Bakke S, Kang M, Robey RW, Zhai S, Thambi P, Chen CC, Patil S, Smith T, Steinberg SM, Merino M, Goldspiel B, Meadows B, Stein WD, Choyke P, ... ... Fojo T, et al. A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 4724-33. PMID 15269145 DOI: 10.1158/1078-0432.Ccr-0829-03  0.56
2004 Mani S, Macapinlac M, Goel S, Verdier-Pinard D, Fojo T, Rothenberg M, Colevas D. The clinical development of new mitotic inhibitors that stabilize the microtubule Anti-Cancer Drugs. 15: 553-558. PMID 15205596 DOI: 10.1097/01.Cad.0000131681.21637.B2  0.56
2004 Stein WD, Bates SE, Fojo T. Intractable cancers: the many faces of multidrug resistance and the many targets it presents for therapeutic attack. Current Drug Targets. 5: 333-46. PMID 15134216 DOI: 10.2174/1389450043345489  0.56
2004 Stein WD, Litman T, Fojo T, Bates SE. A Serial Analysis of Gene Expression (SAGE) database analysis of chemosensitivity: comparing solid tumors with cell lines and comparing solid tumors from different tissue origins. Cancer Research. 64: 2805-16. PMID 15087397 DOI: 10.1158/0008-5472.Can-03-3383  0.56
2003 Goldsmith ME, Kitazono M, Fok P, Aikou T, Bates S, Fojo T. The Histone Deacetylase Inhibitor FK228 Preferentially Enhances Adenovirus Transgene Expression in Malignant Cells Clinical Cancer Research. 9: 5394-5401. PMID 14614025  0.56
2003 Fojo T, Bates S. Strategies for reversing drug resistance Oncogene. 22: 7512-7523. PMID 14576855 DOI: 10.1038/Sj.Onc.1206951  0.56
2003 Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. The Oncologist. 8: 411-24. PMID 14530494 DOI: 10.1634/Theoncologist.8-5-411  0.56
2003 Padmanabhan H, Ehrlich LD, Quazedo M, Fojo T, Louie A, Walther M, Pacak K. Unusual locations of involvement by malignancies: Case 2. Metastatic pheochromocytoma to the colon. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 3369-71. PMID 12947075 DOI: 10.1200/JCO.2003.09.100  0.56
2003 Hiroi N, Kino T, Bassett M, Rainey WE, Phung M, Abu-Asab M, Fojo T, Briata P, Chrousos GP, Bornstein SR. Pituitary homeobox factor 1, a novel transcription factor in the adrenal regulating steroid 11beta-hydroxylase. Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et MéTabolisme. 35: 273-8. PMID 12915995 DOI: 10.1055/s-2003-41301  0.56
2003 Agrawal M, Edgerly M, Fojo T, Kotz H. Treatment of recurrent cervical adenocarcinoma with BMS-247550, an epothilone B analog Gynecologic Oncology. 90: 96-99. PMID 12821348 DOI: 10.1016/S0090-8258(03)00146-X  0.56
2003 Abraham J, Agrawal M, Bakke S, Rutt A, Edgerly M, Balis FM, Widemann B, Davis L, Damle B, Sonnichsen D, Lebwohl D, Bates S, Kotz H, Fojo T. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days Journal of Clinical Oncology. 21: 1866-1873. PMID 12721265 DOI: 10.1200/Jco.2003.03.063  0.56
2003 Loganzo F, Discafani CM, Annable T, Beyer C, Musto S, Hari M, Tan X, Hardy C, Hernandez R, Baxter M, Singanallore T, Khafizova G, Poruchynsky MS, Fojo T, Nieman JA, et al. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Cancer Research. 63: 1838-45. PMID 12702571  0.56
2003 Agrawal M, Abraham J, Balis FM, Edgerly M, Stein WD, Bates S, Fojo T, Chen CC. Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 650-6. PMID 12576431  0.56
2003 Wood BJ, Abraham J, Hvizda JL, Alexander HR, Fojo T. Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases Cancer. 97: 554-560. PMID 12548596 DOI: 10.1002/cncr.11084  0.56
2003 Ireland CM, Aalbersberg W, Andersen RJ, Ayral-Kaloustian S, Berlinck RGS, Bernan V, Carter G, Churchill ACL, Clardy J, Concepcion GP, De Silva ED, Discafani C, Fojo T, Frost P, Gibson D, et al. Anticancer agents from unique natural products sources Pharmaceutical Biology. 41: 15-38. DOI: 10.1080/1388020039051742  0.56
2002 Blagosklonny MV, Robey R, Sackett DL, Du L, Traganos F, Darzynkiewicz Z, Fojo T, Bates SE. Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity Molecular Cancer Therapeutics. 1: 937-941. PMID 12481415  0.56
2002 Sale S, Sung R, Shen P, Yu K, Wang Y, Duran GE, Kim JH, Fojo T, Oefner PJ, Sikic BI. Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers. Molecular Cancer Therapeutics. 1: 215-25. PMID 12467216  0.56
2002 Fojo T. p53 as a therapeutic target: Unresolved issues on the road to cancer therapy targeting mutant p53 Drug Resistance Updates. 5: 209-216. PMID 12450786 DOI: 10.1016/S1368-7646(02)00119-X  0.56
2002 Fojo T, Bates S. Arsenic trioxide (As(2)O(3)): still a mystery Cell Cycle (Georgetown, Tex.). 1: 183-186. PMID 12429931 DOI: 10.4161/Cc.1.3.123  0.56
2002 Blagosklonny MV, Demidenko ZN, Fojo T. Inhibition of transcription results in accumulation of Wt p53 followed by delayed outburst of p53-inducible proteins: p53 as a sensor of transcriptional integrity Cell Cycle (Georgetown, Tex.). 1: 67-74. PMID 12429911 DOI: 10.4161/Cc.1.1.102  0.56
2002 Altaha R, Fojo T, Reed E, Abraham J. Epothilones: A novel class of non-taxane microtubule-stabilizing agents Current Pharmaceutical Design. 8: 1707-1712. PMID 12171542 DOI: 10.2174/1381612023394043  0.56
2002 Giannakakou P, Nakano M, Nicolaou KC, O'Brate A, Yu J, Blagosklonny MV, Greber UF, Fojo T. Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics Proceedings of the National Academy of Sciences of the United States of America. 99: 10855-10860. PMID 12145320 DOI: 10.1073/Pnas.132275599  0.56
2002 Abraham J, Bakke S, Rutt A, Meadows B, Merino M, Alexander R, Schrump D, Bartlett D, Choyke P, Robey R, Hung E, Steinberg SM, Bates S, Fojo T. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: Continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist Cancer. 94: 2333-2343. PMID 12015757 DOI: 10.1002/cncr.10487  0.56
2002 Kitazono M, Chuman Y, Aikou T, Fojo T. Adenovirus HSV-TK construct with thyroid-specific promoter: Enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the camp pathway International Journal of Cancer. 99: 453-459. PMID 11992417 DOI: 10.1002/Ijc.10307  0.56
2002 Bates SE, Chen C, Robey R, Kang M, Figg WD, Fojo T. Reversal of multidrug resistance: Lessons from clinical oncology Novartis Foundation Symposium. 243: 83-102. PMID 11990784 DOI: 10.1002/0470846356.Ch7  0.56
2002 Wood BJ, Ramkaransingh JR, Fojo T, Walther MM, Libutti SK. Percutaneous tumor ablation with radiofrequency Cancer. 94: 443-451. PMID 11900230 DOI: 10.1002/cncr.10234  0.56
2002 Kitazono M, Rao VK, Robey R, Aikou T, Bates S, Fojo T, Goldsmith ME. Histone deacetylase inhibitor FR901228 enhances adenovirus infection of hematopoietic cells Blood. 99: 2248-2251. PMID 11877306 DOI: 10.1182/Blood.V99.6.2248  0.56
2002 Blagosklonny MV, Robey R, Sheikh MS, Fojo T. Paclitaxel-induced fasl-independent apoptosis and slow (non-apoptotic) cell death Cancer Biology and Therapy. 1: 113-117. DOI: 10.4161/Cbt.53  0.56
2002 Kitazono M, Bates S, Fok P, Fojo T, Blagosklonny MV. The histone deacetylase inhibitor FR901228 (depsipeptide) restores expression and function of pseudo-null p53 Cancer Biology and Therapy. 1: 665-668. DOI: 10.4161/Cbt.317  0.56
2002 Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: Role of ATP-dependent transporters Nature Reviews Cancer. 2: 48-58. DOI: 10.1038/Nrc706  0.56
2001 Nicolaou KC, Namoto K, Li J, Ritzén A, Ulven T, Shoji M, Zaharevitz D, Gussio R, Sackett DL, Ward RD, Hensler A, Fojo T, Giannakakou P. Synthesis and biological evaluation of 12,13-cyclopropyl and 12,13-cyclobutyl epothilones. Chembiochem : a European Journal of Chemical Biology. 2: 69-75. PMID 11828429 DOI: 10.1002/1439-7633(20010105)2:1<69::Aid-Cbic69>3.0.Co;2-8  0.56
2001 Bates S, Kang M, Meadows B, Bakke S, Choyke P, Merino M, Goldspiel B, Chico I, Smith T, Chen C, Robey R, Bergan R, Figg WD, Fojo T. A phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (Valspodar) Cancer. 92: 1577-1590. PMID 11745237 DOI: 10.1002/1097-0142(20010915)92:6<1577::Aid-Cncr1484>3.0.Co;2-H  0.56
2001 Poruchynsky MS, Giannakakou P, Ward Y, Bulinski JC, Telford WG, Robey RW, Fojo T. Accompanying protein alterations in malignant cells with a microtubule-polymerizing drug-resistance phenotype and a primary resistance mechanism. Biochemical Pharmacology. 62: 1469-80. PMID 11728383 DOI: 10.1016/S0006-2952(01)00804-8  0.56
2001 Matsumoto Y, Takano H, Kunishio K, Nagao S, Fojo T. Incidence of mutation and deletion in topoisomerase IIα mRNA of etoposide and mAMSA-resistant cell lines Japanese Journal of Cancer Research. 92: 1133-1137. PMID 11676865 DOI: 10.1111/J.1349-7006.2001.Tb01069.X  0.56
2001 Blagosklonny MV, Fojo T, Bhalla KN, Kim JS, Trepel JB, Figg WD, Rivera Y, Neckers LM. The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy. Leukemia. 15: 1537-43. PMID 11587211 DOI: 10.1038/Sj.Leu.2402257  0.56
2001 Fojo T. Cancer, DNA repair mechanisms, and resistance to chemotherapy Journal of the National Cancer Institute. 93: 1434-1436. PMID 11584051 DOI: 10.1093/Jnci/93.19.1434  0.56
2001 Nicoletti MI, Valoti G, Giannakakou P, Zhan Z, Kim JH, Lucchini V, Landoni F, Mayo JG, Giavazzi R, Fojo T. Expression of β-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-anticancer drug screen: Correlation with sensitivity to microtubule active agents Clinical Cancer Research. 7: 2912-2922. PMID 11555610  0.56
2001 Fojo T. Novel_target.com Oncologist. 6: 313-314. PMID 11524547 DOI: 10.1634/theoncologist.6-4-313  0.56
2001 Kitazono M, Goldsmith ME, Aikou T, Bates S, Fojo T. Enhanced adenovirus transgene expression in malignant cells treated with the histone deacetylase inhibitor FR901228 Cancer Research. 61: 6328-6330. PMID 11522619  0.56
2001 Matsumoto Y, Takano H, Kunishio K, Nagao S, Fojo T. Expression of drug resistance genes in VP-16 and mAMSA-selected human carcinoma cells Japanese Journal of Cancer Research. 92: 778-884. PMID 11473729 DOI: 10.1111/J.1349-7006.2001.Tb01161.X  0.56
2001 Kitazono M, Robey R, Zhan Z, Sarlis NJ, Skarulis MC, Aikou T, Bates S, Fojo T. Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the NA+/I- symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells Journal of Clinical Endocrinology and Metabolism. 86: 3430-3435. PMID 11443220 DOI: 10.1210/Jcem.86.7.7621  0.56
2001 Giannakakou P, Robey R, Fojo T, Blagosklonny MV. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: Molecular determinants of paclitaxel-induced cytotoxicity Oncogene. 20: 3806-3813. PMID 11439344 DOI: 10.1038/Sj.Onc.1204487  0.56
2001 Kang MH, Figg WD, Ando Y, Blagosklonny MV, Liewehr D, Fojo T, Bates SE. The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6α-hydroxypaclitaxel, a major metabolite of paclitaxel Clinical Cancer Research. 7: 1610-1617. PMID 11410497  0.56
2001 Blagosklonny MV, Giannakakou P, Romanova LY, Ryan KM, Vousden KH, Fojo T. Inhibition of HIF-1- and wild-type p53-stimulated transcription by codon Arg175 p53 mutants with selective loss of functions Carcinogenesis. 22: 861-867. PMID 11375890 DOI: 10.1093/Carcin/22.6.861  0.56
2001 Pacak K, Fojo T, Goldstein DS, Eisenhofer G, Walther MM, Linehan WM, Bachenheimer L, Abraham J, Wood BJ. Radiofrequency ablation: a novel approach for treatment of metastatic pheochromocytoma. Journal of the National Cancer Institute. 93: 648-9. PMID 11309443 DOI: 10.1093/Jnci/93.8.648  0.56
2001 Mickley L, Jain P, Miyake K, Schriml LM, Rao K, Fojo T, Bates S, Dean M. An ATP-binding cassette gene (ABCG3) closely related to the multidrug transporter ABCG2 (MXR/ABCP) has an unusual ATP-binding domain Mammalian Genome. 12: 86-88. PMID 11178751 DOI: 10.1007/S003350010237  0.56
2001 Nicoletti MI, Myers TG, Fojo T, Blagosklonny MV. Wild-type p53 marginally induces endogenous MDR-1 mRNA without causing a measurable drug resistance in human cancer cells International Journal of Oncology. 18: 375-381. PMID 11172607 DOI: 10.3892/Ijo.18.2.375  0.56
2001 Kitazono M, Chuman Y, Aikou T, Fojo T. Construction of gene therapy vectors targeting thyroid cells: Enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the cyclic adenosine 3′,5′-monophosphate pathway and demonstration of activity in follicular and anaplastic thyroid carcinoma cells Journal of Clinical Endocrinology and Metabolism. 86: 834-840. PMID 11158054 DOI: 10.1210/Jcem.86.2.7196  0.56
2001 Chico I, Kang MH, Bergan R, Abraham J, Bakke S, Meadows B, Rutt A, Robey R, Choyke P, Merino M, Goldspiel B, Smith T, Steinberg S, Figg WD, Fojo T, et al. Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833 Journal of Clinical Oncology. 19: 832-842. PMID 11157037 DOI: 10.1200/Jco.2001.19.3.832  0.56
2001 Matsumoto Y, Takano H, Kunishio K, Nagao S, Fojo T. Hypophosphorylation of topoisomerase IIα in etoposide (VP-16)-resistant human carcinoma cell lines associated with carboxy-terminal truncation Japanese Journal of Cancer Research. 92: 799-805. DOI: 10.1111/J.1349-7006.2001.Tb01164.X  0.56
2001 Matsumoto Y, Takano H, Nagao S, Fojo T. Altered topoisomerase IIα and multidrug resistance-associated protein levels during drug selection: Adaptations to increasing drug pressure Japanese Journal of Cancer Research. 92: 968-974.  0.56
2000 Giannakakou P, Sackett DL, Ward Y, Webster KR, Blagosklonny MV, Fojo T. p53 is associated with cellular microtubules and is transported to the nucleus by dynein Nature Cell Biology. 2: 709-717. PMID 11025661 DOI: 10.1038/35036335  0.56
2000 Abraham J, Fojo T, Wood BJ. Radiofrequency ablation of metastatic lesions in adrenocortical cancer [3] Annals of Internal Medicine. 133: 312-313. PMID 10929185 DOI: 10.7326/0003-4819-133-4-200008150-00028  0.56
2000 Giannakakou P, Gussio R, Nogales E, Downing KH, Zaharevitz D, Bollbuck B, Poy G, Sackett D, Nicolaou KC, Fojo T. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 97: 2904-9. PMID 10688884 DOI: 10.1073/Pnas.040546297  0.56
2000 Chuman Y, Zhan Z, Fojo T. Construction of gene therapy vectors targeting adrenocortical cells: Enhancement of activity and specificity with agents modulating the cyclic adenosine 3′,5′-monophosphate pathway Journal of Clinical Endocrinology and Metabolism. 85: 253-262. PMID 10634396 DOI: 10.1210/Jcem.85.1.6244  0.56
2000 Fojo T, Giannakakou P. Taxol and other microtubule-interactive agents Current Opinion in Oncologic, Endocrine and Metabolic Investigational Drugs. 2: 293-304.  0.56
1998 Sandor V, Fojo T, Bates SE. Future perspectives for the development of P-glycoprotein modulators. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 1: 190-200. PMID 17092805 DOI: 10.1016/S1368-7646(98)80039-3  0.56
1998 Knutsen T, Mickley LA, Ried T, Green ED, du Manoir S, Schröck E, Macville M, Ning Y, Robey R, Polymeropoulos M, Torres R, Fojo T. Cytogenetic and molecular characterization of random chromosomal rearrangements activating the drug resistance gene, MDR1/P-glycoprotein, in drug-selected cell lines and patients with drug refractory ALL. Genes, Chromosomes & Cancer. 23: 44-54. PMID 9713996 DOI: 10.1002/(Sici)1098-2264(199809)23:1<44::Aid-Gcc7>3.0.Co;2-6  0.32
1998 Blagosklonny MV, Giannakakou P, Wojtowicz M, Romanova LY, Ain KB, Bates SE, Fojo T. Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells. The Journal of Clinical Endocrinology and Metabolism. 83: 2516-22. PMID 9661637 DOI: 10.1210/Jcem.83.7.4984  0.56
1998 Mickley LA, Lee J, Weng Z, Zhan Z, Alvarez M, Wilson W, Bates SE, Fojo T. Genetic Polymorphism in MDR-1: A Tool for Examining Allelic Expression in Normal Cells, Unselected and Drug-Selected Cell Lines, and Human Tumors Blood. 91: 1749-1756. DOI: 10.1182/Blood.V91.5.1749.1749_1749_1756  0.56
1997 Zhan Z, Scala S, Monks A, Hose C, Bates S, Fojo T. Resistance to paclitaxel mediated by P-glycoprotein can be modulated by changes in the schedule of administration. Cancer Chemotherapy and Pharmacology. 40: 245-50. PMID 9219509 DOI: 10.1007/s002800050654  0.56
1997 Mickley LA, Spengler BA, Knutsen TA, Biedler JL, Fojo T. Gene rearrangement: a novel mechanism for MDR-1 gene activation. The Journal of Clinical Investigation. 99: 1947-57. PMID 9109439 DOI: 10.1172/Jci119362  0.56
1997 Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, Buolamwini JK, Van Osdol WW, Monks AP, Scudiero DA, Sausville EA, et al. An information-intensive approach to the molecular pharmacology of cancer Science. 275: 343-349. PMID 8994024 DOI: 10.1126/Science.275.5298.343  0.56
Show low-probability matches.